- Report
- May 2024
- 188 Pages
Global
From €3216EUR$3,374USD£2,759GBP
€3573EUR$3,749USD£3,065GBP
- Report
- May 2024
- 93 Pages
Global
From €5337EUR$5,600USD£4,579GBP
- Report
- February 2024
- 175 Pages
Global
From €4766EUR$5,000USD£4,088GBP
- Report
- May 2024
- 164 Pages
Global
From €5194EUR$5,450USD£4,456GBP
- Report
- May 2024
- 78 Pages
Global
From €5337EUR$5,600USD£4,579GBP
- Report
- March 2024
- 160 Pages
Global
From €2383EUR$2,500USD£2,044GBP
- Report
- July 2021
- 92 Pages
Global
From €3200EUR$3,597USD£2,841GBP
- Report
- February 2024
- 97 Pages
Global
From €3500EUR$3,934USD£3,107GBP
Beta Interferon is a type of biotechnology drug used to treat multiple sclerosis (MS). It is a synthetic form of a naturally occurring protein that helps to reduce inflammation and slow the progression of MS. Beta Interferon is administered through injections and is used to reduce the frequency of MS relapses. It is also used to reduce the severity of symptoms and slow the progression of disability.
Beta Interferon is one of the most widely used treatments for MS, and is often prescribed in combination with other therapies. It is also used to treat other neurological conditions, such as chronic inflammatory demyelinating polyneuropathy.
The Beta Interferon market is highly competitive, with several major players offering a range of products. Companies in the market include Biogen, Merck, Novartis, Sanofi, and Teva Pharmaceuticals. Show Less Read more